NASDAQ:VBLT Vascular Biogenics (VBLT) Stock Forecast, Price & News $0.24 0.00 (-0.12%) (As of 05:37 PM ET) Add Compare Share Share Today's Range$0.24▼$0.2650-Day Range$0.21▼$0.3152-Week Range$0.10▼$0.32Volume447,059 shsAverage Volume2.22 million shsMarket Capitalization$18.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Vascular Biogenics (NASDAQ:VBLT) StockVascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.Read More VBLT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VBLT Stock News HeadlinesSeptember 26, 2023 | americanbankingnews.comVascular Biogenics (NASDAQ:VBLT) Now Covered by Analysts at StockNews.comSeptember 9, 2023 | finance.yahoo.comVascular Biogenics Rises on Presentation HypeOctober 2, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 6, 2023 | finance.yahoo.comVBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SECAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 28, 2023 | businesswire.comVASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLTAugust 14, 2023 | finance.yahoo.comVBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 23, 2023 | fool.comVascular Biogenics (NASDAQ: VBLT)October 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 15, 2023 | finance.yahoo.comVBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 4, 2023 | benzinga.comVascular Biogenics Stock (NASDAQ:VBLT), DividendsMarch 17, 2023 | finance.yahoo.comVascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)March 14, 2023 | finance.yahoo.comVBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comVBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in CashFebruary 27, 2023 | prnewswire.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vascular Biogenics Ltd. - VBLTFebruary 23, 2023 | technews.tmcnet.comVBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to ShareholdersFebruary 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vascular Biogenics Ltd. MergerFebruary 23, 2023 | marketwatch.comVascular Biogenics Shares Jump Premarket on Reverse Merger Plans >VBLTFebruary 23, 2023 | msn.comVascular Biogenics rises 85% on all-stock merger deal with Notable LabsFebruary 23, 2023 | investorplace.comWhy Is Vascular Biogenics (VBLT) Stock Up 52%?February 16, 2023 | finance.yahoo.comVBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in CashNovember 10, 2022 | finance.yahoo.comOYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue EstimatesSeptember 2, 2022 | finance.yahoo.comAxsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07September 1, 2022 | finance.yahoo.comVBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencySeptember 1, 2022 | finance.yahoo.comSorrento (SRNE) Gets FDA Fast Track Tag for Back Pain ProductAugust 2, 2022 | marketwatch.comVascular Biogenics Cutting About 35% of Staff >VBLTAugust 2, 2022 | finance.yahoo.comVBL Therapeutics Announces Workforce ReductionSee More Headlines Receive VBLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter. Email Address VBLT Company Calendar Last Earnings8/14/2023Today10/02/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBLT Previous SymbolNASDAQ:VBLX CUSIPN/A CIK1603207 Webwww.vblrx.com Phone(728) 993-5000Fax972-8993-5001Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,300,000.00 Net MarginsN/A Pretax Margin-3,317.05% Return on Equity-73.45% Return on Assets-54.11% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.63 Sales & Book Value Annual Sales$481,000.00 Price / Sales39.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book0.76Miscellaneous Outstanding Shares77,640,000Free Float72,881,000Market Cap$18.95 million OptionableOptionable Beta0.82 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesProf. Dror Harats M.D. (Age 66)CEO & Director Comp: $444.33kMr. Samuel Backenroth (Age 39)Chief Financial Officer Comp: $410kDr. Eyal Breitbart Ph.D. (Age 56)Sr. VP of Research & Operations Advocate Ayelet Horn (Age 52)Gen. Counsel Dr. Erez Feige M.B.A. (Age 49)Ph.D., Sr. VP of Bus. Operations Key CompetitorsProMIS NeurosciencesNASDAQ:PMNKazia TherapeuticsNASDAQ:KZIAOrgenesisNASDAQ:ORGSNanoViricidesNYSE:NNVCCelyad OncologyNASDAQ:CYADView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 100 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions VBLT Stock - Frequently Asked Questions How have VBLT shares performed in 2023? Vascular Biogenics' stock was trading at $0.12 at the start of the year. Since then, VBLT stock has increased by 103.4% and is now trading at $0.2441. View the best growth stocks for 2023 here. When is Vascular Biogenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our VBLT earnings forecast. How were Vascular Biogenics' earnings last quarter? Vascular Biogenics Ltd. (NASDAQ:VBLT) released its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter. What other stocks do shareholders of Vascular Biogenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vascular Biogenics investors own include SCYNEXIS (SCYX), Matinas BioPharma (MTNB), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Aeterna Zentaris (AEZS), Dynavax Technologies (DVAX), Vaxart (VXRT) and Geron (GERN). What is Vascular Biogenics' stock symbol? Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT." How do I buy shares of Vascular Biogenics? Shares of VBLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vascular Biogenics' stock price today? One share of VBLT stock can currently be purchased for approximately $0.24. How much money does Vascular Biogenics make? Vascular Biogenics (NASDAQ:VBLT) has a market capitalization of $18.95 million and generates $481,000.00 in revenue each year. The biopharmaceutical company earns $-32,300,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. How can I contact Vascular Biogenics? Vascular Biogenics' mailing address is 8 HASATAT STREET, MODI IN L3, 7178106. The official website for the company is www.vblrx.com. The biopharmaceutical company can be reached via phone at (728) 993-5000, via email at ir@vblrx.com, or via fax at 972-8993-5001. This page (NASDAQ:VBLT) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vascular Biogenics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.